1. Network meta-analysis of first- and second-generation protease inhibitors for chronic hepatitis C genotype 1: efficacy based on RVR and SVR 24

   • Helena H. Borba
   • Astrid Wiens
   • Roberto Pontarolo

   Review 19 October 2016 Pages: 1 - 14

   

2. Neutralization of EP217609, a new dual-action FIIa/FXa anticoagulant, by its specific antidote avidin: a phase I study

   • P. Gueret
   • S. Combe
   • E. Neuhart

   Clinical Trial 15 October 2016 Pages: 15 - 28

   

3. Hepatic expression of transcription factors affecting developmental regulation of UGT1A1 in the Han Chinese population

   • Ya-li Nie
   • Hang He
   • Quan-cheng Kan

   Pharmacogenetics 05 October 2016 Pages: 29 - 37

   

4. FOXP3 rs3761548 polymorphism is associated with tacrolimus-induced acute nephrotoxicity in renal transplant patients

   • Zhuo Wu
   • Qinxia Xu
   • Mingkang Zhong

   Pharmacogenetics 17 October 2016 Pages: 39 - 47

   

5. Effect of aprepitant, a moderate CYP3A4 inhibitor, on bosutinib exposure in healthy subjects

   • Poe-Hirr Hsyu
   • Daniela Soriano Pignataro
   • Kyle Matschke

   Pharmacokinetics and Disposition 07 October 2016 Pages: 49 - 56

   

6. Effect of bosutinib on the absorption of dabigatran etexilate mesylate, a P-glycoprotein substrate, in healthy subjects

   • Poe-Hirr Hsyu
   • Daniela Soriano Pignataro
   • Kyle Matschke

   Pharmacokinetics and Disposition 07 October 2016 Pages: 57 - 63

   

7. Anti-tuberculosis drug concentrations in tuberculosis patients with and without diabetes mellitus

   • A K Hemanth Kumar
   • V Chandrasekaran
   • Geetha Ramachandran

   Pharmacokinetics and Disposition 20 September 2016 Pages: 65 - 70

   

8. A population pharmacokinetic model to predict oxypurinol exposure in patients on haemodialysis

   • Daniel FB Wright
   • Matthew P. Doogue
   • Lisa K Stamp

   Pharmacokinetics and Disposition 28 September 2016 Pages: 71 - 78

   

9. Adverse drug events in patients with advanced chronic conditions who have a prognosis of limited life expectancy at hospital admission

   • Daniel Sevilla-Sanchez
   • Núria Molist-Brunet
   • Carles Codina-Jané

   Pharmacoepidemiology and Prescription 04 October 2016 Pages: 79 - 89

   

10. Assessing adherence to inhaled corticosteroids in asthma patients using an integrated measure based on primary and secondary adherence

    • Lucie Blais
    • Fatima-Zohra Kettani
    • Francine M. Ducharme

    Pharmacoepidemiology and Prescription 01 October 2016 Pages: 91 - 97

11. Ergot and non-ergot dopamine agonists and heart failure in patients with Parkinson’s disease

    • François Montastruc
    • Florence Moulis
    • Jean-Louis Montastruc

    Pharmacoepidemiology and Prescription 27 October 2016 Pages: 99 - 103

    

12. Characteristics and drug use patterns of older antidepressant initiators in Germany

    • Kathrin Jobski
    • Niklas Schmedt
    • Edeltraut Garbe

    Pharmacoepidemiology and Prescription 18 October 2016 Pages: 105 - 113

    

13. Evaluation of methods to estimate missing days’ supply within pharmacy data of the Clinical Practice Research Datalink (CPRD) and The Health Improvement Network (THIN)

    • Kirsten J. Lum
    • Craig W. Newcomb
    • Vincent Lo Re III

    Pharmacoepidemiology and Prescription 27 October 2016 Pages: 115 - 123

    

14. Benefits of a national network of drug information centres: RELIS

    • Jan Schjøtt

    Letter to the Editor Open access 15 September 2016 Pages: 125 - 126

15. Erratum to: Genotype and co-medication dependent CYP2D6 metabolic activity: effects on serum concentrations of aripiprazole, haloperidol, risperidone, paliperidone and zuclopenthixol

    • Lisbeth Patteet
    • Vincent Haufroid
    • Hugo Neels

    Erratum 13 October 2016 Pages: 127 - 127